In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and - resistant Staphylococcus aureus strains

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2529-2534

  Frosco, Mary Beth ^a   Melton, John L ^a   Stewart, Frances P ^a   Kulwich, Barbara A ^a   Licata, Lisa ^a   Barrett, John F ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HISTOLOGY; PRIORITY JOURNAL; PYELONEPHRITIS; STAPHYLOCOCCUS AUREUS;

EID: 0029861639     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2529     Document Type: Article

References (22)

1. Davis, R., and H. M. Bryson. 1994. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 38:677-700.
2. Dholakia, N., K. V. I. Rolston, D. H. Ho, B. LeBlanc, and G. P. Bodey. 1994. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob. Agents Chemother. 40:848-852.
3. Fernandes, P. B., D. T. W. Chu, R. R. Bower, K. P. Jarvis, N. R. Ramer, and N. Shipkowitz. 1986. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob. Agents Chemother. 29:201-208.
4. Fernandes, P. B., D. T. W. Chu, R N. Swanson, N. R. Ramer, C. W. Hanson, R. R. Bower, J. M. Stamm, and D. J. Hardy. 1988. A-61827 (A-60969), a new fluoronapthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 32:27-32.
5. Fernandes, P. B., and R. N. Swanson. 1988. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies. Drugs Exp. Clin. Res. 14:375-378.
6. Fowler, E. F., J. G. Simpson, and A. W. Thomson. 1980. Histological and ultrastructural changes following carrageenan injection in the mouse. J. Pathol. 132:63-79.
7. Fu, K. P., B. D. Foleno, S. C. Lafredo, J. M. LoCoco, and D. M. Isaacson. 1993. In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 37:301-307.
8. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
9. Fu, K., G. Muller, D. Isaacson, A. J, Tobia, M. E. Rosenthale, and J. L. McGuire. 1989. In vivo efficacy of ofloxacin in experimental pyelonephritis in mice infected with Klebsiella pneumonia, p. 349.1-349.2. In E. Rubenstein and D. Adfam (ed.). Recent advances in chemotherapy. Proceedings of the 16th International Congress on Chemotherapy. E. Lewin-Epstein, Ltd., Jerusalem.
10. Fujimoto, T., and S. Mituhashi. 1992. In vitro antibacterial activity of levofloxacin, the S-(-)-ofloxacin. Chemotherapy (Tokyo) 40(Suppl. 3):1-13.
11. Gargallo-Viola, D. M., M. Esteve, S. Llovera, X. Roca, and J. Guinea. 1991. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob. Agents Chemother. 35:442-447.
12. Goto, S., and S. Miyazaki. 1992. New quinolones. In vivo antibacterial activity. Prog. Drug Res. 38:29-37.
13. Goto, S., S. Miyazaki, and Y. Ishida. 1992. In vitro and in vivo antibacterial activities of levofloxacin (DR-3355) a new quinolone antibacterial. Chemotherapy (Tokyo) 40(Suppl. 3):14-25.
14. Hardy, D. J., R. N. Swanson, D. M. Hensey, N. R. Ramer, R. R. Bower, C. W. Hanson, D. T. W. Chu, and P. B. Fernandes. 1987. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob. Agents Chemother. 31:1768-1774.
15. Ishii, T., A. Ohno, and Y. Yamaguchi. 1994. In vitro antibacterial activities of broad spectrum quinolones against clinical bacterial isolates. Jpn. J. Antibiot. 47:22-28.
16. Klesel, N., K. H. Geweniger, P. Koletzki, D. Isert, M. Limbert, A. Markus, G. Riess, H. Schramm, and P. Iyer. 1995. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J. Antimicrob. Chemother. 35:805-819.
17. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. NCCLS document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Nishino, T., M. Tanaka, Y. Aono, et al. 1992. In vivo and in vitro antibacterial activity of levofloxacin. Chemotherapy (Tokyo) 40(Suppl. 3):36-50.
19. Schwenke, J. R., and G. A. Milliken. 1991. On the calibration problem extended to nonlinear models. Biometrics 47:563-574.
20. Yamane, N., R. N. Jones, R. Frei, D. J. Hoban, A. C. Pignatari, and F. Marco. 1994. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J. Chemother. 6:83-91.
21. Yokota, T., E. Suzuki, K. Arai, and K. Kanda. 1992. in vitro antibacterial activity of levofloxacin, its selective toxicity and influence on axon dendrites. Chemotherapy (Tokyo) 40(Suppl. 3):27-35.
22. Zak, O., F. Kradolfer, E. A. Knopka, S. Kunz, and A. Batt. 1978. CPG 7174/E (Takeda SCE 129): activity against systemic and urinary track infections in mice and rats, p. 846-848. In W. Siegenthaler and R. Lüthy (ed.), Current chemotherapy. Proceedings of the 10th International Congress on Chemotherapy. American Society for Microbiology, Washington, D.C.